Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly stock soars following data suggesting its Alzheimer's drug can slow illness
06:02pm, Wednesday, 03'rd May 2023
Shares of Eli Lilly and Company surge after drug trial data suggests the pharmaceutical company's Alzheimer's treatment drug can potentially slow the illness.
Eli Lilly's positive results from a Alzheimer's trial seen as ‘potentially very important'
02:07pm, Wednesday, 03'rd May 2023
Positive results from an Alzheimer's trial by Eli Lilly are seen as a very important step in the battle to fight the fatal disease, but questions remain about whether it will be covered by Medicare.
Why Eli Lilly Stock Is Bolting Higher Today
01:59pm, Wednesday, 03'rd May 2023
Eli Lilly announced better-than-expected trial results for its early-stage Alzheimer's disease candidate, donanemab, today. The drug's latest results paint an encouraging picture for patients.
SNY or LLY: Which Is the Better Value Stock Right Now?
12:55pm, Wednesday, 03'rd May 2023
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Sanofi (SNY) or Eli Lilly (LLY). But which of these two companies is the best option for those lookin
Promising data from Eli Lilly shows a significant slowdown in the pace of Alzheimer's
12:20pm, Wednesday, 03'rd May 2023
CNBC's Bertha Coombs joins 'Squawk on the Street' to discuss Eli Lilly receiving an upgrade following news that the company's Alzheimer's treatment drug Donanemab significantly slows disease progressi
Biogen Stock Hits Fresh High on Eli Lilly Buzz
10:59am, Wednesday, 03'rd May 2023
The shares of Biogen Inc (NASDAQ:BIIB) are enjoying tailwinds from positive news surrounding sector peer Eli Lilly's (LLY) Alzheimer's drug donanemab.
Cramer's First Take: Eli Lilly's Alzheimer's drug is 'the holy grail'
10:54am, Wednesday, 03'rd May 2023
CNBC's Jim Cramer shares his thoughts on Eli Lilly's Alzheimer's drug and the banking turmoil.
Eli Lilly's Results Signal Arrival of Blockbuster New Drug Class
10:16am, Wednesday, 03'rd May 2023
The company's Alzheimer's drug results might look better than Biogen's, but both makers will likely benefit.
Eli Lilly's Alzheimer's drug slowed cognitive decline in phase 3 study
09:56am, Wednesday, 03'rd May 2023
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's Alzheimer's treatment donanemab, which slowed disease progression in the phase 3 trial.
LLY Stock Alert: Eli Lilly Announces Positive Alzheimer's Drug Data
09:44am, Wednesday, 03'rd May 2023
Eli Lilly (NYSE: LLY ) stock is getting a boost on Wednesday after the company announced results from an Alzheimer's clinical trial. The big news traders are celebrating is the effectiveness of donane
Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises
09:16am, Wednesday, 03'rd May 2023
Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline. The post Eli Lilly Surges After Alzheimer's Treatment Succeeds; B
Good News for Patients Is Lifting These 2 Biopharma Stocks
08:46am, Wednesday, 03'rd May 2023
Markets were waiting to see what the Federal Reserve will do with interest rates later today. Eli Lilly announced favorable trial results for its Alzheimer's treatment.
U.S. stock futures inch higher as traders await Fed decision
08:37am, Wednesday, 03'rd May 2023
U.S. stock index futures on Wednesday were recovering a portion of the previous session's sharp selloff, as the focus turns to the Federal Reserve interest rate decision later in the day, while privat
Eli Lilly jumps upon Alzheimer trial results, AMD, Starbucks and Ford drop after earnings, and other stocks on the move
07:48am, Wednesday, 03'rd May 2023
Livent Corp. shares LTHM jumped nearly 10% premarket Wednesday after the lithium miner posted first-quarter results that topped Wall Street views and raised guidance.
Eli Lilly Stock Jumps on Positive Alzheimer's Drug Phase 3 Trial Data
06:34am, Wednesday, 03'rd May 2023
The company says a Phase 3 study shows that donanemab 'significantly slowed cognitive and functional decline' in people with early symptomatic Alzheimer's disease.
